Emcure Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Emcure Pharmaceuticals Ltd reported a 9.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were down by 6.9% QoQ and - - YoY.
- The net profit decreased 22.5% QoQ and - - YoY.
- The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 6.4 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1783.10 | 1966.53 | 0.00 | -9.3% | - |
Total Expenses | 1616.05 | 1736.61 | 0.00 | -6.9% | - |
Profit Before Tax | 166.90 | 229.92 | - | -27.4% | NaN% |
Tax | 45.89 | 73.83 | 0.00 | -37.8% | - |
Profit After Tax | 121.02 | 156.09 | 0.00 | -22.5% | - |
Earnings Per Share | 6.40 | 8.10 | 0.00 | -21.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its diverse range of pharmaceuticals and healthcare products. The company operates in the global market, manufacturing and marketing a wide array of drugs, including formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas. As of the data available, no specific recent major developments are provided. Emcure has built a reputation for innovation and quality, with a strong presence in both domestic and international markets. The company is committed to delivering affordable healthcare solutions and enhancing accessibility to essential medications.
Revenue
In the fourth quarter of fiscal year 2025, Emcure Pharmaceuticals Ltd reported a total income of ₹1783.10 crores, marking a decrease of 9.3% from the previous quarter (Q3FY25), which recorded a total income of ₹1966.53 crores. Year-over-year comparison with Q4FY24 is not feasible due to lack of data for the previous year. The decline in revenue on a quarter-over-quarter basis is evident from the provided financial figures, reflecting changes in market dynamics or operational factors during this period.
Profitability
The company's profitability metrics for Q4FY25 highlight a profit before tax of ₹166.90 crores, which shows a significant decline of 27.4% compared to the previous quarter (Q3FY25), where the profit before tax was ₹229.92 crores. The tax expense for Q4FY25 amounted to ₹45.89 crores, decreasing by 37.8% from Q3FY25. Consequently, the profit after tax for Q4FY25 was reported at ₹121.02 crores, down by 22.5% from Q3FY25's ₹156.09 crores. Earnings per share (EPS) for Q4FY25 stood at ₹6.40, declining by 21.0% from the EPS of ₹8.10 in Q3FY25. The reduction in profitability metrics on a quarter-over-quarter basis is notable, reflecting the financial performance trends for this reporting period.
Operating Metrics
The analysis of operating metrics for Q4FY25 reveals total expenses of ₹1616.05 crores, which have decreased by 6.9% from the previous quarter's expenses of ₹1736.61 crores. This reduction in expenses is a key operational aspect for the quarter. However, due to the absence of year-over-year data for Q4FY24, the analysis is confined to quarter-over-quarter comparisons. The operating metrics illustrate the cost management efforts undertaken during this period, with a focus on controlling expenses amidst a decrease in total income.